Compare RLGT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLGT | REPL |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.1M | 407.1M |
| IPO Year | 2006 | 2018 |
| Metric | RLGT | REPL |
|---|---|---|
| Price | $9.36 | $10.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 9 |
| Target Price | ★ $8.00 | $5.67 |
| AVG Volume (30 Days) | 155.2K | ★ 3.1M |
| Earning Date | 05-08-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.75 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $902,696,000.00 | N/A |
| Revenue This Year | $2.13 | N/A |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | $40.96 | ★ N/A |
| Revenue Growth | ★ 12.49 | N/A |
| 52 Week Low | $5.78 | $1.50 |
| 52 Week High | $9.68 | $13.24 |
| Indicator | RLGT | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 62.42 |
| Support Level | $8.68 | $9.69 |
| Resistance Level | $9.45 | $12.50 |
| Average True Range (ATR) | 0.22 | 0.90 |
| MACD | -0.01 | -0.19 |
| Stochastic Oscillator | 63.27 | 42.83 |
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.